Romundstad Solfrid, Hatlen Gudrun, Hallan Stein I
aDepartment of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim bDepartment of Internal Medicine, Levanger Hospital, Health Trust Nord-Trøndelag, Levanger cDepartment of Nephrology dDepartment of Emergency, Clinic of Emergency Medicine and Prehospital Care, St. Olav University Hospital, Trondheim, Norway.
J Hypertens. 2016 Oct;34(10):2081-9. doi: 10.1097/HJH.0000000000001035.
Knowledge on how changing risk factors influence the progression of albuminuria over time is still limited. Furthermore, large population-based cohorts are needed to study the association between albuminuria change and mortality risk in nondiabetic study participants.
We evaluated changes of albuminuria in 6282 nondiabetic individuals from the Norwegian population-based Nord-Trøndelag Health study. Using three albumin/creatinine ratios (ACR), we studied the influence of cardiovascular risk factors on ACR change from baseline to follow-up 11 years later. We evaluated the next 8-year mortality risk by using flexible parametric methods to identify nonlinear main effects and their two-way interactions.
Mean albuminuria increased significantly over 11 years (1.82-3.02 mg/mmol, P < 0.0001), but two-thirds of individuals had stable levels (ΔACR -1.40 to 1.40 mg/mmol). Higher age, ACR, and SBP as well as smoking and lower glomerular filtration rate at baseline were associated with increasing albuminuria. Study participants in the upper quartile of the increasing group had mean adjusted hazard ratio 1.31 (P = 0.004) for all-cause mortality compared with those with stable ACR. Those with decreasing ACR also had increased mortality, but the risk was strongly attenuated when adjusting for comorbidity. It also decreased the first 3 years before increasing. There was a strong interaction between baseline ACR and ΔACR. Increasing albuminuria had strongest effect on mortality in study participants with moderately increased baseline values.
Both increasing and decreasing albuminuria are significant independent predictors of mortality in nondiabetic individuals, but must be interpreted in light of baseline values. Cutoffs and clinical usefulness in nondiabetic study participants should be further investigated.
关于风险因素变化如何随时间影响蛋白尿进展的知识仍然有限。此外,需要大规模基于人群的队列研究来探讨非糖尿病研究参与者中蛋白尿变化与死亡风险之间的关联。
我们评估了来自挪威基于人群的北特伦德拉格健康研究中的6282名非糖尿病个体的蛋白尿变化。使用三种白蛋白/肌酐比值(ACR),我们研究了心血管风险因素对11年后从基线到随访时ACR变化的影响。我们使用灵活的参数方法来识别非线性主效应及其双向相互作用,评估接下来8年的死亡风险。
11年间平均蛋白尿显著增加(从1.82至3.02mg/mmol,P<0.0001),但三分之二的个体水平稳定(ACR变化为-1.40至1.40mg/mmol)。更高的年龄、ACR和收缩压以及吸烟和基线时较低的肾小球滤过率与蛋白尿增加相关。与ACR稳定的参与者相比,增加组上四分位数的研究参与者全因死亡率的平均调整风险比为1.31(P=0.004)。ACR降低的参与者死亡率也增加,但在调整合并症后风险大幅降低。它在增加前的前3年也有所下降。基线ACR与ΔACR之间存在强烈相互作用。蛋白尿增加对基线值中度升高的研究参与者的死亡率影响最强。
蛋白尿增加和降低都是非糖尿病个体死亡的重要独立预测因素,但必须结合基线值进行解释。非糖尿病研究参与者的临界值和临床实用性应进一步研究。